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Gastrointestinal and Metabolic Problems Associated With 
Immunosuppression With Either CyA or FK 506 in Liver 
Transplantation 
D.H. Van Thiel, M. Iqbal, A. Jain, J. Fung, S. Todo, and T.E. Starzl 
SINCE its introduction in 1979. CyA has been the immunosuppression agent of choice in clinical trans-
plantation of all solid organs. I More recently, a novel new 
immunosuppressive agent, FK 506, has been introduced in 
experimental transplantation.2 Most recently. it also has 
been introduced into clinical liver transplantation. Both 
agents appear to be T cell-specific and induce their immu-
nosuppressive effects by impairing interleukin-2 produc-
tion and receptor expression.3 Presumably. CyA initiates 
its immunosuppressive actions by an intracellular protein 
(receptor), cyclophillin. and by interacting with one or 
more calcium-binding proteins.4 In contrast, FK 506 ap-
pears to bind to a completely different intracellular protein. 
putatively called fugiphillin. Because these two drugs act 
via different binding proteins. and presumably follow dif-
ferent intermediate steps to produce T cell suppression. we 
have compared the two in terms of their untoward gastro-
intestinal and metabolic effects in liver transplant patients. 
METHODS 
Subjects 
The first 20 patients receiving a primary liver graft with FK 506 
immunosuppression were matched for age (in all but two cases). 
gender. primary liver disease diagnosis. and United Network 
Organ Sharing (UNOS) score with a patient receiving a primary 
liver graft under CyA immunotherapy at the same institution 
during the preceding 2 yean;. Each FK S06 subject. with two 
exceptions. was matched for age within 5 yean; with a control and 
identically for all other characteristics identified above (gender, 
liver disease. UNOS score). 
Assays 
Pretransplant levels of serum uric acid, cholesterol. and amylase, 
as well as fasting blood sugar were determined on all subjects. 
Every patient transplanted under FK S06 immunosuppression 
had each measurement repeated at 10 days and again 15-20 days 
posttransplantation. When available. similar data for the controls 
transplanted under Cy A were obtained from the medical records 
at approximately similar time points following liver transplanta-
tion. 
Symptom Survey 
Each patient treated with FK S06 was seen daily from day 
postoperatively through day 20 and assessed for the presence of 
each of the signs or symptoms listed in Table I. Whenever any 
gastrointestinal symptoms are identified posttransplantation. up-
per gastrointestinal panendoscopy with biopsy of the duodenum 
and gastric antrum was performed. Endoscopy had been per-
formed preoperatively on aD subjects (both FK S06 and eyA-
Table 1. Symptom Survey Utilized 
Gastrointestinal hems 
Nausea 
Vomiting 
Retching 
Abdominal pain 
Abdominal cramps 
Diarrhea 
Incontinence, stool 
Incontinence, urine 
Neurologic Items 
Headache 
Dizziness 
Tremor 
Seizure 
Psychosis 
ToxiC encephalopathy 
TIngling 
Numbness 
treated patients). and the endoscopic and biopsy findings found 
postoperatively were compared both between groups and for pre-
and post-liver transplantation changes. For this purpose, two 
endoscopic biopsies from the duodenum and two from the gastric 
antrum were fixed overnight in 10% buffered formalin. sectioned 
at S /Lm, stained with hematoxylin and eosin, and reviewed by 
staff pathologists at the Presbyterian-University Hospital. Pitts-
burgh. PA. 
The charts of the 20 controls treated with Cy A were reviewed 
retrospectively for evidence of any of the 16 signs and symptoms 
assessed prospectively and daily in the FK S06-treated patients. 
All values are reported as means :!: SEM. Significant differ-
ences between groups were determined using either the student's 
r test (two-tailed) or Jl analysis. A P value of <0.05 was 
considered to be significant. 
RESULTS 
The age. gender, liver disease diagnosis. and UNOS score 
for each FK 506- and Cy A-treated patient are shown in 
Table 2. As noted in this table, each FK 506- and CyA-
treated patient was identically matched for gender. pri-
mary liver disease, and UNOS score. An attempt was 
made to match each FK 506 patient with a CyA-treated 
patient of the same age ::: 5 years. and this was possible 
with all but two patients (nos. 4 and 10). As a result, no 
significant difference for age was seen between the two 
groups. As evidenced by the UN OS scores, both real 
number and the mean value. these patients were all quite ill 
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Table 2. Characteristics of the Two Groups of Subjects Studied 
FK506 Liver Disease UNOS 
Patients Gender Age Diagnosis" Score Age" 
M 31 PSC 2 35 
2 M 18 Alagille's 1 18 
3 M 38 PNC-NANB 3 35 
4 M 19 PSC 3 28 
5 M 43 PNC-C 45 
6 M 38 PNC-NANB 4 43 
7 M 42 PNC-ETOH 1 46 
8 M 39 PNC-ETOH 4 40 
9 F 41 PNC-B 2 36 
10 F 49 Budd-Chiari 4 25 
11 M 49 PSC 2 45 
12 M 28 Caroli's 2 24 
13 F 41 PBC 2 44 
14 F 55 PBC 2 55 
15 F 37 PNC-ETOH 3 33 
16 M 55 PNC-ETOH 3 58 
17 M 41 PNC-ETOH 3 44 
18 F 33 PBC 1 42 
19 F 64 PNC-C 2 64 
20 F 43 PNC-ETOH 2 41 
Mean::!: SEM 40.2 ::!: 2.5 2.5::!: 0.2 40.1 ::!: 2.6 
Abbreviatioos: PSC. primary sclerosing chofang~is; PNC·NANB. post-necrotic cirrhosis due to putative NANB; PNC-C. cryptogenic post-necrotic: cirrhosis; PNC·ETOH. 
aJcohotic cirmosis; PNC-B. posHleCrOOC cirmosis due to hepatitis B virus; PSC. primary biliary cirmosis. 
" Age of matched CyA control patients. 
and would have been candidates for liver transplantation at 
any center in the world. 
The mean pre- and post-liver transplantation serum 
levels of uric acid, cholesterol, and amylase, and the 
fasting blood sugar levels for each patient are shown in 
Table 3. The serum uric acid levels increased significantly 
in both groups when pre- and post-liver transplantation 
values were compared. No difference between groups for 
pre- and post-liver transplantation uric acid values was 
evident. 
The serum cholesterol level declined significantly (P = 
0.037) in the FK 506-treated group and increased arithmet-
ically but not significantly in the CyA-treated group. As a 
result, a highly significant difference (P = 0.015) between 
groups was evident for the post-liver transplantation cho-
lesterol levels, whereas no difference existed in the pre-
liver transplantation values. 
The serum amylase values did not differ significantly 
pre-liver transplantation and decreased post-liver trans-
plantation in both groups. In neither group was the reduc-
tion statistically significant, but the post-liver transplanta-
tion level in the FK 506-treated group was significantly less 
<P = 0.048) than that of the CyA-treated group. 
The fasting blood sugar levels did not differ within and 
between groups pre- and post-liver transplantation. For 
each group, an arithmetic but insignificant increase was 
noted following transplantation. These differences are not 
biologically significant. 
Abdominal computed tomography (CT) scans were 
available in all patients studied preoperatively and in the 
Table 3. Serum Uric Acid, Cholesterol, Amylase, and Fasting Blood Sugar Before and After Liver Transplantation 
In the Patients Studied 
Parameter Group Pretranspianlation 
Uric acid (mg/dl) FK506 4.5::!: 0.4" 
CyA 4.2::!: 0.5 
Cholesterol (mgldl) FK506 2OO.5::!: 37.3 
CyA 148.5::!: 25.0 
Amylase (IUJ\.) FK 506 163::!: 86 
CyA 108 ::!: 13 
Fasting blood sugar (mgldI) FK506 107 ::!: 8.0 
CyA 127::!: 12.0 
" Not signifICantly diflerenl'rom the pretransplantation level in the CyA-treated group. 
t Not significantly diflerent from the posltransplantation level in the CyA·treated group. 
Posttransplantation 
7.8::!: 1.ot 
6.2::!: 0.9 
123.7::!: 9K~ 
168.5::!: 5.6 
53::!: 5* 
79::!: 12 
137:!: 19 
134 ::!: 19 
* SIgnifICantly difterenl from .. value 'Of the CyA-treated group at the same time in relation to the liver transplantation. 
PValue 
0.007 
0.063 
0.037 
0.382 
0.222 
0.079 
0.110 
0.644 
CYA VERSUS FK 506 IN LIVER TRANSPLANTATION 
majority of patients studied postoperatively. No evidence 
for pancreatic inflammatory disease was evident in either 
group before or after liver transplantation. 
The two groups differed for only two of the 16 signs and 
symptoms assessed. The FK 506 group experienced vom-
iting (P = 0.026) while the CyA-treated group experienced 
more abdominal pain (P = 0.023). When all 16 symptoms 
and signs of potential adverse reaction were pooled, no 
difference between the two groups was evident. 
Thirteen of the Cy A-treated controls had abdominal CT 
scans both before and after liver transplantation. No 
evidence of pancreatic disease developed in any of these 
controls as a consequence of transplantation. Six of the 
FK 506-treated patients had abdominal CT scans obtained 
both pre- and post-liver transplantation. Again, no change 
in the appearance of the pancreas was evident between 
these two studies. 
cr scans of the head were obtained for four CyA-
treated patients and four FK 506-treated patients. Small to 
moderate volume loss was seen pre- and post-liver trans-
plantation in two of the individuals transplanted for alco-
holic liver disease. No abnormalities not present pretrans-
plantation developed in either group posttransplantation. 
DISCUSSION 
The data obtained in highly matched patients undergoing 
primary liver transplantation with either standard Cy A or 
FK 506 immunosuppression demonstrate several impor-
tant findings relative to the long-term use of both immu-
nosuppressive agents.4 
First, both agents result in a moderale, albeit not clini-
cally important, increase in serum uric acid levels (Table 
3). The increase following liver transplantation was greater 
arithmetically but not statistically in the FK 506-treated 
group. It is well-established that CyA has a variety of 
nephrotoxic actions, one of which is to impair uric acid 
excretion, resulting in an increase in the serum uric acid 
level and the potential for clinical uric acid arthropathy and 
nephropathy.s It appears from these data that FK 506 may 
do the same. It remains to be shown. however. whether 
the increase in uric acid levels in the FK 506-treated 
patients is the result of increased production or reduced 
excretion rate. The latter mechanism would appear more 
likely, but no data are currently available to distinguish 
between these two possibilities. 
Second, CyA is known to enhance the production of 
cholesterol as a result of up-regulation of the rate-limiting 
enzyme involved in cholesterol biosynthesis. HMG-Co-a 
reductase. 6 Moreover. CyA increases plasma levels oflow 
density lipoproteins and apolipoprotein B. Both mecha-
nisms result in about a 30% increase in serum cholesterol 
levels with prolonged use of CyA. The present data 
demonstrate a CyA-associated arithmetic increase in se-
rum cholesterol, and a significant FK S06 reduction in 
serum cholesterol between pre- and post-liver transplanta-
tion values (Table 3). This difference between the two 
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drugs may have very important implications for the long-
term survival of both patients and grafts. as a result of 
atherosclerosis and chronic rejection, as occurs as a result 
of foam cell obliteration of vascular lumina. At present, no 
such statement can be made, but. should this difference in 
cholesterol levels persist with a longer experience with FK 
506. this finding should enhance the acceptability of FK 
506 as the agent of choice for chronic immunosuppression. 
should all other factors be equal. 
Third. despite the preliminary experience in animals, 
that FK 506 can produce a patchy pancreatic acinar 
necrosis and vasculitis which clinically might be termed a 
drug-induced form of pancreatitis. no evidence for pancre-
atitis was seen in either patient group studied.7•9 Specifi-
cally, the serum amylase declined in both groups postop-
eratively. with the decline being greater in the FK 506-
treated group than in the CyA-treated patients. Moreover. 
neither group showed a significant alteration in the level of 
fasting blood sugar or pancreatic morphology assessed by 
abdominal cr scanning obtained pre- and post-liver trans-
plantation. Thus, despite the worrisome experience in 
animals, the present early experience with FK S06 in 
humans does not support the observation that FK S06 is a 
pancreatic toxic drug. 
Finally, although both drugs have been associated with 
a wide spectrum of transient abdominal and neurologic 
signs and symptoms, little or no difference was seen for 16 
common signs and symptoms experienced by transplant 
recipients and thought to be a result of the immunosup-
pressive agents used to control or prevent rejection (Table 
1). 
Transient vomiting appeared more commonly in patients 
treated with FK 506 (f = 0.026). while transient abdominal 
pain occurred more often in those on CyA (P = 0.023). The 
clinical significance of these findings is uncertain, as both 
were transient, no specific abnormality could be identified 
as the cause for either of these two complaints. and no 
specific therapy appeared to alleviate them. In both 
groups. they appeared as minor inconveniences rather 
than as problems that necessitated a change in therapy or 
:~;:~r u.:.tion. This experience differs considerably from the 
experience in experimental animals. such as the dog and 
rat. 7-13 The relative absence of abnormalities found follow-
ing liver transplantation on endoscopy of the upper gastro-
intestinal tract and the histologic findings found in the 
gastric antrum and duodenum of the two groups of sub-
jects studied were surprising. 
In summary, the preliminary short-term experience with 
FK 506 suggests that FK 506 compares well with CyA as 
the primary immunosuppressive agent used in a liver 
transplant population. The reduction in serum cholesterol 
seen with FK 506. as opposed to CyA, may be an advan-
tage with a longer experience. Both agents appeared to 
increase serum uric acid levels and neither adversely 
affected pancreatic function. as assessed in this prelimi-
nary investigation. 
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